{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:38:24Z","timestamp":1791261504879,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","award":["HI14C2399"],"award-info":[{"award-number":["HI14C2399"]}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology","award":["2011-0008846"],"award-info":[{"award-number":["2011-0008846"]}]},{"name":"SNUH Research Fund","award":["03-2010-0080"],"award-info":[{"award-number":["03-2010-0080"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00280-016-3103-x","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T15:28:27Z","timestamp":1468596507000},"page":"533-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia"],"prefix":"10.1007","volume":"78","author":[{"given":"Jeong-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chansu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Sub","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Sung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Lae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Doo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,15]]},"reference":[{"key":"3103_CR1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.1989.7.1.45","volume":"7","author":"JL Harousseau","year":"1989","unstructured":"Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N (1989) Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 7:45\u201349","journal-title":"J Clin Oncol"},{"key":"3103_CR2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ajh.23544","volume":"88","author":"A Nazha","year":"2013","unstructured":"Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S (2013) Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients\u00a0\u226460\u00a0years with newly diagnosed acute myeloid leukemia. Am J Hematol 88:961\u2013966","journal-title":"Am J Hematol"},{"key":"3103_CR3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","volume":"30","author":"S Faderl","year":"2012","unstructured":"Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM (2012) Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial. J Clin Oncol 30:2492\u20132499","journal-title":"J Clin Oncol"},{"key":"3103_CR4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","volume":"26","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26:621\u2013629","journal-title":"Leuk Res"},{"key":"3103_CR5","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nbt1350","volume":"25","author":"F Ishikawa","year":"2007","unstructured":"Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, Nakamura R, Tanaka T, Tomiyama H, Saito N, Fukata M, Miyamoto T, Lyons B, Ohshima K, Uchida N, Taniguchi S, Ohara O, Akashi K, Harada M, Shultz LD (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25:1315\u20131321","journal-title":"Nat Biotechnol"},{"key":"3103_CR6","first-page":"2241","volume":"27","author":"M Tsujie","year":"2007","unstructured":"Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M (2007) Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res 27:2241\u20132249","journal-title":"Anticancer Res"},{"key":"3103_CR7","first-page":"895","volume":"91","author":"S Marce","year":"2006","unstructured":"Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M, Colomer D (2006) Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91:895\u2013902","journal-title":"Haematologica"},{"key":"3103_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-1-4615-1173-1_2","volume":"112","author":"ML Clarke","year":"2002","unstructured":"Clarke ML, Mackey JR, Baldwin SA, Young JD, Cass CE (2002) The role of membrane transporters in cellular resistance to anticancer nucleoside drugs. Cancer Treat Res 112:27\u201347","journal-title":"Cancer Treat Res"},{"key":"3103_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11899-013-0156-3","volume":"8","author":"ND Reese","year":"2013","unstructured":"Reese ND, Schiller GJ (2013) High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep 8:141\u2013148","journal-title":"Curr Hematol Malig Rep"},{"key":"3103_CR10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.2217\/pgs.09.118","volume":"10","author":"JK Lamba","year":"2009","unstructured":"Lamba JK (2009) Genetic factors influencing cytarabine therapy. Pharmacogenomics 10:1657\u20131674","journal-title":"Pharmacogenomics"},{"key":"3103_CR11","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","volume":"68","author":"J Cai","year":"2008","unstructured":"Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P (2008) Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 68:2349\u20132357","journal-title":"Cancer Res"},{"key":"3103_CR12","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.bjc.6602881","volume":"93","author":"I Hubeek","year":"2005","unstructured":"Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ (2005) The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93:1388\u20131394","journal-title":"Br J Cancer"},{"key":"3103_CR13","doi-asserted-by":"crossref","first-page":"e37203","DOI":"10.1371\/journal.pone.0037203","volume":"7","author":"P Macanas-Pirard","year":"2012","unstructured":"Macanas-Pirard P, Leisewitz A, Broekhuizen R, Cautivo K, Barriga FM, Leisewitz F, Gidi V, Riquelme E, Montecinos VP, Swett P, Besa P, Ramirez P, Ocqueteau M, Kalergis AM, Holt M, Rettig M, DiPersio JF, Nervi B (2012) Bone marrow stromal cells modulate mouse ENT1 activity and protect leukemia cells from cytarabine induced apoptosis. PLoS One 7:e37203","journal-title":"PLoS One"},{"key":"3103_CR14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s12185-015-1766-4","volume":"101","author":"J Amaki","year":"2015","unstructured":"Amaki J, Onizuka M, Ohmachi K, Aoyama Y, Hara R, Ichiki A, Kawai H, Sato A, Miyamoto M, Toyosaki M, Machida S, Kojima M, Shirasugi Y, Kawada H, Ogawa Y, Ando K (2015) Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. Int J Hematol 101:543\u2013553","journal-title":"Int J Hematol"},{"key":"3103_CR15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejca.2012.07.022","volume":"49","author":"KI Kim","year":"2013","unstructured":"Kim KI, Huh IS, Kim IW, Park T, Ahn KS, Yoon SS, Yoon JH, Oh JM (2013) Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. Eur J Cancer 49:403\u2013410","journal-title":"Eur J Cancer"},{"key":"3103_CR16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13046-014-0090-9","volume":"33","author":"H Wan","year":"2014","unstructured":"Wan H, Zhu J, Chen F, Xiao F, Huang H, Han X, Zhong L, Zhong H, Xu L, Ni B, Zhong J (2014) SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res 33:90","journal-title":"J Exp Clin Cancer Res"},{"key":"3103_CR17","first-page":"351","volume":"88","author":"C Schoch","year":"2003","unstructured":"Schoch C, Schnittger S, Kern W, Dugas M, Hiddemann W, Haferlach T (2003) Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1897 patients with acute myeloid leukemia. Haematologica 88:351\u2013352","journal-title":"Haematologica"},{"key":"3103_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1086\/338688","volume":"70","author":"DJ Schaid","year":"2002","unstructured":"Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70:425\u2013434","journal-title":"Am J Hum Genet"},{"key":"3103_CR19","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1016\/S0021-9258(19)70512-2","volume":"255","author":"DW Kufe","year":"1980","unstructured":"Kufe DW, Major PP, Egan EM, Beardsley GP (1980) Correlation of cytotoxicity with incorporation of ara-C into DNA. J Biol Chem 255:8997","journal-title":"J Biol Chem"},{"key":"3103_CR20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.2002.03538.x","volume":"117","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E, Dumontet C (2002) In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117:860\u2013868","journal-title":"Br J Haematol"},{"key":"3103_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/138920107780487465","volume":"8","author":"J Styczynski","year":"2007","unstructured":"Styczynski J (2007) Drug resistance in childhood acute myeloid leukemia. Curr Pharm Biotechnol 8:59\u201375","journal-title":"Curr Pharm Biotechnol"},{"key":"3103_CR22","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood.V100.9.3352","volume":"100","author":"CM Zwaan","year":"2002","unstructured":"Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Huismans DR, Zimmermann M, Harbott J, Slater RM, Creutzig U, Veerman AJ (2002) Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities. Blood 100:3352\u20133360","journal-title":"Blood"},{"key":"3103_CR23","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ajh.23549","volume":"88","author":"IJ Falk","year":"2013","unstructured":"Falk IJ, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Hoglund M, Palmqvist L, Stockelberg D, Wei Y, Green H, Lotfi K (2013) Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5\u2019-nucleotidase. Am J Hematol 88:1001\u20131006","journal-title":"Am J Hematol"},{"key":"3103_CR24","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood-2008-05-154302","volume":"113","author":"CM Hartford","year":"2009","unstructured":"Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, Lamba JK, Huang RS, Dolan ME (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113:2145\u20132153","journal-title":"Blood"},{"key":"3103_CR25","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbrc.2009.10.094","volume":"390","author":"G Jin","year":"2009","unstructured":"Jin G, Matsushita H, Asai S, Tsukamoto H, Ono R, Nosaka T, Yahata T, Takahashi S, Miyachi H (2009) FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun 390:1001\u20131006","journal-title":"Biochem Biophys Res Commun"},{"key":"3103_CR26","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1182\/blood-2012-10-464149","volume":"121","author":"ER Gamazon","year":"2013","unstructured":"Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME (2013) Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood 121:4366\u20134376","journal-title":"Blood"},{"key":"3103_CR27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/01.fpc.0000189804.41962.15","volume":"16","author":"SN Myers","year":"2006","unstructured":"Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, Ferrell RE (2006) Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genom 16:315\u2013320","journal-title":"Pharmacogenet Genom"},{"key":"3103_CR28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00439-006-0218-x","volume":"120","author":"JM Chen","year":"2006","unstructured":"Chen JM, Ferec C, Cooper DN (2006) A systematic analysis of disease-associated variants in the 3\u2019 regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3\u2019UTR variants. Hum Genet 120:301\u2013333","journal-title":"Hum Genet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3103-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3103-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3103-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T04:10:38Z","timestamp":1656821438000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3103-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["3103"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3103-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,15]]}}}